Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 6Cytarabine 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 3Etoposide 3Cyclophosphamide 3Busulfan 3Biopsy 3romidepsin 2perifosine 2laromustine 2decitabine and cedazuridine drug combination 2Tretinoin 2Specimen Handling 2Methotrexate 2Hydroxyurea 2Decitabine 2Daunorubicin 2Cyclosporine 2Antilymphocyte Serum 2venetoclax 1veliparib 1valspodar 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1iadademstat 1gamma-Globulins 1Voriconazole 1Vincristine 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myelodysplastic-Myeloproliferative Diseases × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡